刊名:Journal of Pharmaceutical and Biomedical Analysis
出版年:2017
出版时间:5 February 2017
年:2017
卷:134
期:Complete
页码:130-136
全文大小:643 K
卷排序:134
文摘
Neratinib is an orally available TKI targeting EGRR and HER2 in clinical development. An LC–MS/MS assay from 2 to 1000 ng/mL in 0.1 mL plasma was developed and validated. Signal degradation was observed but corrected with isotopic internal standard. Assay is being utilized to support neratinib combination clinical studies.